Hepatitis B virus reverse transcriptase sequence variant database for sequence analysis and mutation discovery

被引:51
作者
Rhee, Soo-Yon [1 ]
Margeridon-Thermet, Severine
Nguyen, Mindie H.
Liu, Tommy F.
Kagan, Ron M. [2 ]
Beggel, Bastian [3 ]
Verheyen, Jens [4 ]
Kaiser, Rolf [4 ]
Shafer, Robert W.
机构
[1] Stanford Univ, Med Ctr, Div Infect Dis, Dept Med, Stanford, CA 94305 USA
[2] Quest Diagnost Inc, San Juan Capistrano, CA USA
[3] Max Planck Inst Informat, Saarbrucken, Germany
[4] Univ Cologne, Inst Virol, Cologne, Germany
关键词
Hepatitis B virus; Reverse transcriptase (RT); Drug resistance mutation; Database; Nucleoside and nucleotide RT inhibitors (NRTIs; NtRTIs); RESISTANCE; POLYMERASE; HBV;
D O I
10.1016/j.antiviral.2010.09.012
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Drug resistance resulting from reverse transcriptase (RI) mutations is one of the main obstacles to successful hepatitis B virus (HBV) therapy. Indeed, HBV treatment guidelines recommend HBV genotypic resistance testing for patients receiving nucleos(t)ide RT inhibitors (N(t)RTIs) who develop virological failure. N(t)RTI-resistance mutations at 10 RT positions have been well characterized in phenotypic studies, however, data are lacking on the relative frequency of these mutations in N(t)RTI-treated and untreated individuals. There are also few published data on the extent of amino acid variation at most of the 344 positions of HBV RI and the extent to which this variation is influenced by N(t)RTI treatment. We retrieved 23,871 HBV RI sequences from GenBank and reviewed the published reports of these sequences to ascertain the number of individuals from whom the sequences were obtained, the N(t)RTI treatments of these individuals, and the year and region of virus sampling. We then used these data to populate a relational database we named HBVrtDB. As of July 2010, HBVrtDB contained 6811 sequences from 3869 individuals reported in 281 references. Among these 3869 individuals, 73% were N(t)RTI-naive and 27% received one or more N(t)RTIs. Among the 10 well-characterized N(t)RTI-resistance mutations, L80I/V, V173L, L180M, A181T, T184S, S202G and M204I/V were significantly assocated with treatment with lamivudine, an L-nucleoside analog, and A181S/T/V and N236T were significantly associated with treatment with adefovir, an acyclic nucleoside phosphonate. A similar analysis of ten additional less well-characterized resistance mutations demonstrated a significant association with N(t)RTI treatment for four of the mutations: L82M, S85A, A200V, and Q215S. We also created an interactive program, HBVseq, to enable users to identify mutations in submitted sequences and retrieve the prevalence of these mutations in HBVrtDB according to genotype and N(t)RTI treatment. HBVrtDB and HBVseq are available at http://hivdb.stanford.edu/HBV/releaseNotes/. (C) 2010 Elsevier B.V. All rights reserved.
引用
收藏
页码:269 / 275
页数:7
相关论文
共 20 条
[1]  
Bartholomeusz A, 2004, ANTIVIR THER, V9, P149
[2]   CONTROLLING THE FALSE DISCOVERY RATE - A PRACTICAL AND POWERFUL APPROACH TO MULTIPLE TESTING [J].
BENJAMINI, Y ;
HOCHBERG, Y .
JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES B-STATISTICAL METHODOLOGY, 1995, 57 (01) :289-300
[3]   Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC) [J].
Das, K ;
Xiong, XF ;
Yang, HL ;
Westland, CE ;
Gibbs, CS ;
Sarafianos, SG ;
Arnold, E .
JOURNAL OF VIROLOGY, 2001, 75 (10) :4771-4779
[4]   HepSEQ: International public health repository for hepatitis B [J].
Gnaneshan, Saravanamuttu ;
Ijaz, Samreen ;
Moran, Joanne ;
Ramsay, Mary ;
Green, Jonathan .
NUCLEIC ACIDS RESEARCH, 2007, 35 :D367-D370
[5]   Naturally occurring variants of hepatitis B virus [J].
Günther, S ;
Fischer, L ;
Pult, I ;
Sterneck, M ;
Will, H .
ADVANCES IN VIRUS RESEARCH, VOL 52, 1999, 52 :25-137
[6]   Chronic hepatitis B: Preventing, detecting, and managing viral resistance [J].
Keeffe, Emmet B. ;
Dieterich, Douglas T. ;
Pawlotsky, Jean-Michel ;
Benhamou, Yves .
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2008, 6 (03) :268-274
[7]   A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: 2008 Update [J].
Keeffe, Emmet B. ;
Dieterich, Douglas T. ;
Han, Steven-Huy B. ;
Jacobson, Ira M. ;
Martin, Paul ;
Schiff, Eugene R. ;
Tobias, Hillel .
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2008, 6 (12) :1315-1341
[8]   Geographical and genetic diversity of the human hepatitis B virus [J].
Kurbanov, Fuat ;
Tanaka, Yasuhito ;
Mizokami, Masashi .
HEPATOLOGY RESEARCH, 2010, 40 (01) :14-30
[9]   Characterization of potential antiviral resistance mutations in hepatitis B virus reverse transcriptase sequences in treatment-naive Chinese patients [J].
Liu, Bao-Ming ;
Li, Tong ;
Xu, Jie ;
Li, Xiao-Guang ;
Dong, Jian-Ping ;
Yan, Ping ;
Yang, Jing-Xian ;
Yan, Ling ;
Gao, Zhi-Yong ;
Li, Wen-Peng ;
Sun, Xie-Wen ;
Wang, Yu-Hua ;
Jiao, Xiu-Juan ;
Hou, Chun-Sheng ;
Zhuang, Hui .
ANTIVIRAL RESEARCH, 2010, 85 (03) :512-519
[10]   Antiviral drug-resistant HBV: Standardization of nomenclature and assays and recommendations for management [J].
Lok, Anna S. ;
Zoulim, Fabien ;
Locarnini, Stephen ;
Bartholomeusz, Angeline ;
Ghany, Marc G. ;
Pawlotsky, Jean-Michel ;
Liaw, Yun-Fan ;
Mizokami, Masashi ;
Kuiken, Carla .
HEPATOLOGY, 2007, 46 (01) :254-265